Pamela Contreras

TL;DR: Because Y14F mutation diminishes metastasis without inhibiting the tumor suppressor function of CAV1, Y14 phosphorylation emerges as an attractive therapeutic target to prevent metastasis to the lung without altering beneficial traits ofCAV1.

TL;DR: AT2R activation reduces migration, invasion, and metastasis of cancer cells by PTP1B-mediatedCAV1 dephosphorylation and inhibition of the CAV1/Rab5/Rac1 pathway, which opens up interesting, novel therapeutic opportunities to treat metastatic cancer disease.

TL;DR: CAV1 is identified here as a novel substrate for PTPN14 and it is shown that overexpression of this phosphatase suffices to reduce CAV1-induced metastasis.

TL;DR: In this paper, the authors investigated whether this pathway is activated in MDA-MB-231 breast cancer cells and in B16F10 melanoma cells when stimulated with Thy-1.

TL;DR: CAV1-dependent tumor suppression in the absence of E-cadherin is linked to reduced Hif1α transcriptional activity via diminished NOS-mediated HIF1α S-nitrosylation.